Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.56B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.22M
Average 1.74M
NRIX Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Nurix Therapeutics, Inc.NASDAQ: NRIX
Operating Margin · Q3 FY2026 · quarter ended Aug 2026
Operating margin widens to 83.1%
Operating margin was 83.1% in Q3 FY2026, up 1240.8 pp from a year earlier. On a trailing-twelve-month basis it was 41.3%, up 360.6 pp year over year. Over 3 fiscal years it widened by 135.8 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of 60.2% for the fiscal year ending Nov 2026, up from -340.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterAug 2026
- 83.1%+1124.9 pp QoQ
- Last fiscal yearNov 2025
- -340.2%+50.4 pp YoY
- LTMAug 2026
- 41.3%+360.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -340.2%
- Year-over-year change
- +50.4pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-11-30 | -340.2% | +50.4pp |
| FY2024 | 2024-11-30 | -390.5% | -189.1pp |
| FY2023 | 2023-11-30 | -201.4% | +274.6pp |
| FY2022 | 2022-11-30 | -476.0% | -79.8pp |
| FY2021 | 2021-11-30 | -396.3% | — |
Operating Margin vs competitors
How NRIX compares with its peers on the latest reported figures
- NRIX's LTM Aug 2026 operating margin of 41.3% is the 2nd highest of the 7 companies compared; the peer median is -252.5%.
- Its year-over-year change of +360.6 pp is the 3rd highest of 7, against a peer median of +93.8 pp.
- Over three fiscal years its change of +135.8 pp compares with a peer median of +107.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 41.6% | +19.9 pp | +88.8 pp | |
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Mar 2026 | -102.9% | +683.7 pp | — | |
| FY2025 | -178.4% | +167.7 pp | +268.4 pp | |
| LTM Mar 2026 | -326.6% | -33.6 pp | +125.9 pp | |
| LTM Jun 2026 | -333.5% | +364.0 pp | -547.0 pp | |
| LTM Mar 2026 | -443.5% | -144.3 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NRIX) | -252.5% | +93.8 pp | +107.4 pp | |
Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Revenue | 29.75M | 38.63M | 76.99M | 54.55M | 83.98M |
| Cost of Revenue | 116.43M | 184.5M | 189.15M | 221.63M | 18.86M |
| Gross Profit | (86.68M) | (145.87M) | (112.16M) | (167.08M) | 65.12M |
| Gross Margin | -291.4% | -377.6% | -145.7% | -306.3% | 77.5% |
| Research & Development | 116.43M | 184.5M | 189.15M | 221.63M | 308.16M |
| Selling, General & Admin | 31.2M | 38M | 42.9M | 45.94M | 52.74M |
| Operating Expenses | 31.2M | 38M | 42.9M | 45.94M | 350.79M |
| Depreciation & Amortization | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| EBITDA | (110.98M) | (169.55M) | (130.29M) | (176.87M) | (244.84M) |
| EBITDA Margin | -373.0% | -438.9% | -169.2% | -324.2% | -291.5% |
| Operating Income | (117.89M) | (183.87M) | (155.06M) | (213.03M) | (285.67M) |
| Operating Margin | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Interest Income | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 823K | 3.51M | 11.12M | 19.73M | 21.97M |
| Income Before Tax | (117.06M) | (180.36M) | (143.95M) | (193.3M) | (263.7M) |
| Pre-Tax Margin | -393.5% | -466.9% | -187.0% | -354.4% | -314.0% |
| Income Tax Expense | 131K | 0 | 0 | 270K | 760K |
| Net Income | (117.19M) | (180.36M) | (143.95M) | (193.57M) | (264.46M) |
| Net Margin | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| EPS (Basic) | (2.73) | (3.71) | (2.65) | (2.88) | (3.05) |
| EPS (Diluted) | (2.73) | (3.71) | (2.65) | (2.88) | (3.05) |
| Weighted Avg Shares | 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
| Weighted Avg Shares (Diluted) | 42.9M | 48.61M | 54.34M | 67.12M | 86.67M |
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Intrinsic Alpha fair value
Locked
Current Price
$14.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.